Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of long-acting subcutaneous risperidone suspension (TV-46000) for maintenance treatment of schizophrenia
MOH_2019-10-29_007249Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing TV-46000 subcutaneous injection with TV-46000 subcutaneous injection + placebo (2 arms). Started Oct 2019; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on MOH_2019-10-29_007249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-29_007249.